For years, CRISPR Therapeutics (CRSP 1.25%) has been the type of stock investors might call a home run swing. The company ...
One company dominates with an approved therapy, while the other bets on in vivo innovation. See how their financials and risk ...
With few treatments available for sickle cell disease, encouraging early clinical data for a Fulcrum Therapeutics drug made it one to watch. But another medicine from the same drug class was recently ...
5don MSN
New 'SMArT' platform makes gene editing in hematopoietic stem cells more efficient and safer
A team of researchers led by Luigi Naldini at the San Raffaele Telethon Institute for Gene Therapy (SR-Tiget) has developed a ...
Vertex's new drugs are gaining momentum as Alyftrek tops $1 billion in sales and Journavx prescriptions accelerate.
Despite Vertex Pharmaceuticals' underperformance relative to the healthcare sector over the past year, Wall Street analysts ...
A team of researchers led by Luigi Naldini at the San Raffael Institute for Gene Therapy (SR-Tiget) has developed a new ...
Vertex Pharmaceuticals (NASDAQ:VRTX | VRTX Price Prediction) screens as a long-duration compounder because it sits on a global monopoly in cystic fibrosis therapies that generates substantial free ...
Jefferies Global Healthcare Conference 2026 June 3, 2026 9:55 AM EDTCompany ParticipantsSamarth Kulkarni - CEO ...
Zacks Investment Research on MSN
Vertex stock down nearly 8% in 3 months: Time to buy or stay cautious?
Vertex Pharmaceuticals Incorporated VRTX stock has declined 7.9% in the past three months. One major reason for the weakness ...
MarketBeat on MSN
CRISPR Therapeutics enters 'second phase' as CASGEVY momentum builds, pipeline data looms
3 Biotech Stocks That Could Benefit from the Patent Cliff CRISPR Therapeutics (NASDAQ:CRSP) Chief Executive Officer Sam Kulkarni said the company is entering a "second phase" as it moves beyond the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results